Biocon announced that the U.S. FDA conducted a pre approval inspection of the company's new Oral Solid Dosage Forms manufacturing facility at Biocon Park, Bengaluru from November 05 to November 09, 2018. The audit concluded without any observations and no Form 483 was issued.
The stock had outperformed the market over the past one month till Nov. 09, 2018, rising 6.26% compared with the Sensex's 2.50% rise. It outperformed the market in past one quarter, gaining 11.79% as against 7.54% fall in the Sensex.
